RxDoctor Payments Data

Atul Aggarwal, MD

Interventional Cardiology · Bakersfield, CANPI 1043290778

Payments from drug & device makers

$14,939in general payments, 2019–2025

Across 397 payments — averaging $37.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$6K
  • Amgen$2K
  • Merck$1K
  • AstraZeneca$878
  • Boehringer Ingelheim$786
  • Shockwave Medical, Inc$528
  • plus $4K from 33 others

What the payments were for

  • Speaking & faculty fees$5,25035%
  • Travel & lodging$2462%
  • Food & beverage$9,33462%
  • Education$1091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,939 in reported general payments places this provider in the 55th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$1,506,455
Medicare patients
3,297
Services billed
11,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban923$1,078,930
JardianceEmpagliflozin212$229,726
XareltoRivaroxaban137$179,111
Repatha SureclickEvolocumab184$172,371
EntrestoSacubitril/Valsartan135$150,238
Praluent PenAlirocumab65$54,737
OzempicSemaglutide23$22,749
TrulicityDulaglutide19$21,778
VascepaIcosapent Ethyl54$21,058
Amiodarone Hcl283$20,533
Atorvastatin Calcium2,266$19,537
CorlanorIvabradine Hcl16$17,691
Repatha SyringeEvolocumab14$16,696
Ezetimibe431$16,368
BrilintaTicagrelor14$16,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$5,989$1,078,930923 claims
Boehringer IngelheimJardiance$786$229,726212 claims
Johnson & JohnsonXarelto$171$179,111137 claims
NovartisEntresto$266$150,238135 claims
Novo NordiskOzempic$41$22,74923 claims
AmgenCorlanor$1,666$17,69116 claims
AstraZenecaBrilinta$878$16,31114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →